Regulatory Advisory: Detailed Summary of Recent CMS Interim Final Rule on COVID-19 Testing and Treatment

Rule also includes COVID-19 related changes to the Comprehensive Care for Joint Replacement Model

The Centers for Medicare & Medicaid Services (CMS) Oct. 28 announced an interim final rule establishing additional Medicare hospital payment to support Medicare beneficiaries’ access to COVID-19 vaccines and new treatments when they become available. CMS also released information on hospital billing for the outpatient administration of potential monoclonal antibody products; price transparency for COVID-19 tests; additional COVID-19 information relating to private health plans and Medicaid; and COVID-19-related changes to the Comprehensive Care for Joint Replacement (CJR) model. The rule also states that Medicare will cover any preventive vaccine at no cost to beneficiaries so long as it receives Food and Drug Administration approval via an emergency use authorization or Biologics License Application.

You must be logged in as a AHA Non-Fed Member to view the PDF file below with the full Regulatory Advisory.

Related Resources

Letter/Comment
Public
The American Hospital Association (AHA) urges Congress to call on the Centers for Medicare…
Advancing Health Podcast
In this Advancing Health podcast, Thomas Haederle discusses the pandemic's profound impact on CMS's Hospital Quality Measurement and Value programs.
Advancing Health Podcast
In this Members in Action podcast, Julia Resnick, director of strategic initiatives at the AHA, and Thomas Harris, Jr., Executive Vice President of Operations…
Advancing Health Podcast
Public
Leading care teams through COVID-19 has been a challenge unlike any other.
Advancing Health Podcast
Public
The COVID-19 pandemic has had a devastating impact on the health care workforce.
Letter/Comment
Public
AHA provides feedback on the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S.4348).